NASDAQ:PROG
Delisted

Progenity Stock News

etoro logo Buy PROG
*Your capital is at risk
$0.94
-0.0340 (-3.48%)
At Close: Aug 17, 2022
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, announced today that it intends to offer and sell, subject to market
Progenity, Inc. (PROG) CEO Harry Stylli on Q2 2021 Results - Earnings Call Transcript
Progenity, Inc. (PROG) delivered earnings and revenue surprises of 18.75% and -97.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1,
With July only a week away, which penny stocks are investors watching right now? The post Hot Penny Stocks to Buy in 2021?
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Boar
Investors need to pay close attention to Progenity (PROG) stock based on the movements in the options market lately.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder of
Looking for penny stocks under $5? Check these 3 out The post Hot Penny Stocks to Buy Under $5?
Progenity Inc (NASDAQ: PROG) has announced results from a preclinical study evaluating the delivery of PGN-001 (adalimumab liquid formulation) drug substance directly to the colon in an animal mode
Two Abstracts Support Company's Targeted Therapeutics Program including the Drug Delivery System Two Abstracts Support Company's Targeted Therapeutics Program including the Drug Delivery System
Provides educational resources for both patients and healthcare providers Provides educational resources for both patients and healthcare providers
Progenity, Inc. (PROG) CEO Dr. Harry Stylli on Q1 2021 Results - Earnings Call Transcript
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter
Studies show location accuracy and tolerability of the novel oral Drug Delivery System (DDS) and point to a materially enhanced therapeutic/safety index for PGN-600 Studies show location accuracy and
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE